DNALite Therapeutics
Pioneering oral therapies for intestinal delivery of mRNA and pDNA, transforming proteins into oral drugs.
Pioneering oral therapies for intestinal delivery of mRNA and pDNA, transforming proteins into oral drugs.
DNALite Therapeutics Analysis
DNALite Therapeutics is a preclinical biotechnology company founded in 2016 with a focus on transforming proteins into oral drugs. The company's pioneering oral therapies for intestinal delivery of mRNA and pDNA are aimed at leveraging the unique properties of the gastrointestinal tract to secrete proteins into the bloodstream.
The company's slogan, "Pioneering oral therapies for intestinal delivery of mRNA and pDNA, transforming proteins into oral drugs," encapsulates their innovative approach to drug delivery. DNALite Therapeutics has received a Convertible Note investment on 07 March 2023 from notable investors including SOSV and indiebio.
DNALite Therapeutics operates within the Biotechnology and Health Care industries, positioning itself at the forefront of advancements in oral medication technologies.
Overall, DNALite Therapeutics' pioneering approach to oral lipid nanoparticle technology and its recent investment from renowned investors underscore the company's potential to revolutionize drug delivery methods, making it a compelling prospect for venture capital firms seeking innovative biotech opportunities.| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Convertible Note | Unknown | 2 |
|
07 Mar 2023 |
| Series A | $5.60M | 2 |
|
14 Apr 2022 |
| Grant | $967.34K | 1 |
|
28 Dec 2021 |
| Convertible Note | Unknown | 2 |
|
14 Apr 2021 |
| Seed Round | Unknown | 2 |
|
06 Jun 2019 |
No recent news or press coverage available for DNALite Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
